It's certainly affected by discoveries made in other countries, but I think what we're trying to achieve with the patient-oriented research strategy is to take full benefit of the discoveries that are made in this country and ensure they do impact the health of Canadians. We have a clinical research infrastructure that attracts clinical trials from the private sector, which we are losing to an alarming extent to other countries, particularly Asia and eastern Europe, on one hand, because their prices are not competitive--and I'm not sure how much we'll be able to change that--but also because we're not sufficiently organized, we're over-regulated, we're not sufficiently networked, so we're slow to recruit patients.
It's extremely important to have these investments, if only because they give rapid access to Canadian patients to the newest drugs and they also give the opportunity of maintaining a culture of scientific excellence and evidence-based practice in the milieu of care. Part of the strategy is to increase our competitiveness internationally to attract these contracts from the private sector as well as to ensure that innovations made in this country actually benefit Canadians.